(Press-News.org) CINCINNATI—Cincinnati Cancer Center (CCC) and University of Cincinnati (UC) Cancer Institute researchers have found in a phase-1 study that patients with advanced melanoma and kidney cancer who were treated with a certain antibody that targets a tumor-enhancing protein was safe, which could lead to more treatment options for patients.
The study is published in the March 11 edition of PLOS ONE, a peer-reviewed, open access online publication.
Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says this study sheds light on a therapy that could be used alone or in combination to help patients with a number of cancers.
"Transforming growth factor-beta (TGFβ) is a protein that helps cells maintain their functions, from formation to transition to death," Morris says. "Early in the transition of cancers from premalignancy to malignancy, TGFβ can suppress cell growth; however, in advanced cancers, these effects are typically lost, and TGFβ will directly promote the growth and spread of tumors.
"TGFβ-caused cellular changes have been described in many different tumor models and appear to be important for causing cell migration and promoting spread of cancer. Increased TGFβ has been reported in many different cancers including prostate, breast, lung, pancreatic, renal cell, or kidney, liver and more, and elevated plasma TGFβ levels correlate with advanced tumor stage, metastases and poor survival. Given this data, the protein is being examined for potential therapeutic targets."
He adds that in preclinical models, using antibodies or receptors that hinder TGFβ have shown antitumor activity.
"In animal models, effects of anti-TGFβ combined with various chemotherapies, radiation or other biologic-related treatments, including vaccines, have been reported to improve the treatment of both primary and metastatic disease," Morris says. "GC1008, or fresolimumab, is a human antibody that neutralizes the active forms of human TGFβ.
"GC1008 was investigated as a treatment for cancer and fibrotic diseases. We wanted to test the safety of this treatment in repeated doses for patients with malignant melanoma (skin cancer) and renal cell carcinoma (kidney cancer)."
In the study, which was conducted at the National Cancer Institute and a number of cancer centers in the U.S., patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at varying doses. Patients who were stabilized, with no progression of the cancer, were eligible to receive extended treatment consisting of four doses of GC1008 every two weeks for up to two additional rounds.
Pharmacokinetic and exploratory biomarker assessments were performed.
"Twenty-nine patients, 28 with malignant melanoma and one with renal cell carcinoma, were enrolled and treated with 22 in the dose-escalation portion and seven in a safety cohort arm, with one consistent dose delivered," Morris says. "No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe."
He adds that four patients developed reversible squamous-cell carcinomas (a type of skin cancer), one malignant melanoma patient experienced a partial positive response to treatment and six had stable disease with a progression-free survival of 24 weeks.
"GC1008 showed an acceptable safety profile when administered up to 15 mg/kg every two weeks," Morris says. "This preliminary evidence of antitumor activity indicates that additional studies are needed to help determine the efficacy and safety of GC1008 alone and in combination with other treatments, as well as define dose and response."
INFORMATION:
This study was funded by Genzyme Corporation and the National Cancer Institute. Morris cites no conflict of interest.
The University of Cincinnati, Cincinnati Children's Hospital Medical Center and UC Health have created the Cincinnati Cancer Center—a joint effort designed to leverage the strengths of all three organizations in order to provide the best possible cancer diagnostics, research, treatment, and care for individuals in the Tristate region and the nation. To learn more, visit cincinnaticancercenter.org.
Antibody could be used to target tumor-causing protein, study shows
2014-03-11
ELSE PRESS RELEASES FROM THIS DATE:
Examining potential of clinical applications of whole-genome sequencing
2014-03-11
In an exploratory study involving 12 adults, the use of whole-genome sequencing (WGS) was associated with incomplete coverage of inherited-disease genes, low reproducibility of detection of genetic variation with the highest potential clinical effects, and uncertainty about clinically reportable findings, although in certain cases WGS will identify genetic variants warranting early medical intervention, according to a study in the March 12 issue of JAMA.
As technical barriers to human DNA sequencing decrease and costs approach $1,000, whole-genome sequencing (WGS) is ...
Discrepancies between trial results reported on clinical trial registry and in journals
2014-03-11
During a one year period, among clinical trials published in high-impact journals that reported results on a public clinical trial registry (ClinicalTrials.gov), nearly all had at least 1 discrepancy in the study group, intervention, or results reported between the 2 sources, including discrepancies in the designated primary end points for the studies, according to a study in the March 12 issue of JAMA.
The 2007 Food and Drug Administration (FDA) Amendments Act expanded requirements for ClinicalTrials.gov, mandating results reporting within 12 months of trial completion ...
Study finds comparable outcomes for commonly used surgeries to treat vaginal prolapse
2014-03-11
For women undergoing surgery for vaginal prolapse and stress urinary incontinence, neither of 2 common repair procedures was superior to the other for functional or adverse event outcomes, and behavioral therapy with pelvic muscle training did not improve urinary symptoms or prolapse outcomes after surgery, according to a study in the March 12 issue of JAMA.
Pelvic organ prolapse (protrusion) occurs when the uterus descends into the lower vagina or vaginal walls protrude beyond the vaginal opening, and can occur as a result of childbirth. Approximately 300,000 surgeries ...
Study examines development of peer review research in biomedicine
2014-03-11
An analysis of research on peer review finds that studies aimed at improving methods of peer review and reporting of biomedical research are underrepresented and lack dedicated funding, according to a study in the March 12 issue of JAMA.
Mario Malicki, M.D., M.A., of the University of Split School of Medicine, Split, Croatia, and colleagues analyzed research presented at the International Congress on Peer Review and Biomedical Publication (PRC) since 1989. The first PRC was organized to "subject the editorial review process to some of the rigorous scrutiny that editors ...
Discontinuation of randomized clinical trials common
2014-03-11
Approximately 25 percent of about 1,000 randomized clinical trials initiated between 2000 and 2003 were discontinued, with the most common reason cited being poor recruitment of volunteers; and less than half of these trials reported the discontinuation to a research ethics committee, or were ever published, according to a study in the March 12 issue of JAMA.
Conducting high-quality randomized clinical trials (RCTs) is challenging and resource-demanding. Trials are often not conducted as planned or are prematurely discontinued, which poses ethical concerns, particularly ...
Two surgeries for pelvic prolapse found similarly effective, safe
2014-03-11
Two surgical treatments for a form of pelvic hernia affecting women have similar rates of success and safety, scientists in a National Institutes of Health research network have found. A guided exercise therapy to strengthen pelvic muscles did not add to the benefits of either surgery.
The surgical procedures and exercise therapy are used to treat pelvic organ prolapse, an often uncomfortable and sometimes painful weakening of the pelvic organs that may affect women in the years after childbirth. Previous network research suggests that about 3 percent of U.S. women will ...
Incontinence and Prolapse procedures found to be comparable in women
2014-03-11
MAYWOOD – Two common procedures to treat pelvic organ prolapse without vaginal mesh are comparable in safety and efficacy, according to research published in the latest issue of the Journal of the American Medical Association. Researchers also found that behavioral and pelvic floor muscle therapy (BPMT) did not improve urinary incontinence or prolapse symptoms in affected women.
Pelvic organ prolapse occurs when the uterus and/or vaginal walls protrude outside of the body. Up to 73 percent of these women report other pelvic floor disorders such as incontinence. More ...
Whole-genome sequencing for clinical use faces many challenges, Stanford study finds
2014-03-11
STANFORD, Calif. — Whole-genome sequencing has been touted as a game-changer in personalized medicine. Clinicians can identify increases in disease risk for specific patients, as well as their responsiveness to certain drugs, by determining the sequence of the billions of building blocks, called nucleotides, that make up their DNA.
Now, researchers at the Stanford University School of Medicine have discovered that although life-changing discoveries can be made, significant challenges must be overcome before whole-genome sequencing can be routinely clinically useful. In ...
Giving dangerous employees socialization, close supervision can avoid problems
2014-03-11
Two UT Arlington management professors argue that employers can prevent workplace violence by keeping dangerous employees positively engaged and closely supervising them to ensure they get the help they need.
James Campbell Quick and M. Ann McFadyen of the College of Business management department analyzed FBI reports, case studies and human resource records to focus on the estimated 1 to 3 percent of employees prone to workplace acts of aggression, such as homicide, suicide or destruction of property.
The team advances the case for "mindfully observing" employees and ...
Long-term warming likely to be significant despite recent slowdown
2014-03-11
A new NASA study shows Earth's climate likely will continue to warm during this century on track with previous estimates, despite the recent slowdown in the rate of global warming.
This research hinges on a new and more detailed calculation of the sensitivity of Earth's climate to the factors that cause it to change, such as greenhouse gas emissions. Drew Shindell, a climatologist at NASA's Goddard Institute for Space Studies in New York, found Earth is likely to experience roughly 20 percent more warming than estimates that were largely based on surface temperature observations ...